Mark Katz, MD, an adjunct professor at MSIH, co-authored the study with peers from Harvard University, published in the New England Journal of Medicine. This joint BGU & Harvard University study of the Pfizer vaccine confirms its effectiveness, proving to be 94% effective just 1 week after the second dose.

Dr. Katz is currently on the High Threat Pathogens team of the European Regional Office of the WHO, where he is overseeing work related to COVID-19 vaccine monitoring and evaluation in the European region. He is involved in work on vaccine-preventable diseases at the Clalit Research Institute, the research arm of the Clalit Health Services, Israel’s largest HMO.

This study was also highlighted in the Times of Israel.